

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/CAC614E3038EN.html>

Date: February 2018

Pages: 54

Price: US\$ 3,500.00 (Single User License)

ID: CAC614E3038EN

Abstracts

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2018

SUMMARY

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e is a human gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen (CEA) family of proteins. It promotes tumor development through its role as a cell adhesion molecule. It regulates differentiation, apoptosis, and cell polarity.

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 1 and 2 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology and Gastrointestinal which include indications Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma, Colorectal Cancer, Crohn's Disease (Regional Enteritis), Epithelial Ovarian Cancer, Medullary Thyroid Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pancreatic Cancer, Peritoneal Tumor, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.

The latest report Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H1 2018, outlays comprehensive information on the Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)

The report reviews Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and

industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics and enlists all their major and minor projects

The report assesses Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5
(Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or
CEACAM5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Overview
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Companies Involved in Therapeutics Development

Akshaya Bio Inc

Bavarian Nordic A/S

Etubics Corp

OSE Immunotherapeutics

Vaxon Biotech

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Drug Profiles
CV-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DK-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-6207 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSE-2101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Activate CEACAM5 for Crohn's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CEA for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CEA for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-026 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Dormant Products
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Discontinued

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen...

Products

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Product Development Milestones

Featured News & Press Releases

Jan 25, 2018: OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi in Immuno-Oncology Applications

Dec 07, 2017: OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

Jun 23, 2017: OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi in Advanced Lung Cancer

Mar 21, 2017: Direct Tumor Vaccination Shown to Induce Anti-tumor Immunity and Increase Survival in a Murine Model of Pancreatic Cancer

Mar 10, 2017: Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer

Jan 24, 2017: OSE Immunotherapeutics Announces That the Independent Data Monitoring Committee Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi in Non-Small Cell Lung Cancer

Jan 04, 2017: Bristol-Myers, Bavarian Nordic test Opdivo-plus-vaccine combo in lung cancer

Dec 29, 2016: Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer

Aug 15, 2016: Bavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study

Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer

Feb 04, 2016: OSE Pharma Announces U.S. Initiation of Atalante 1, the Company's Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer

Jan 06, 2016: OSE Pharma Announces Initiation of Its Pivotal Phase 3 Trial of Tedopi in Non-Small Cell Lung Cancer

Sep 29, 2015: OSE Pharma to participate to the Large & Midcap Event in Paris on October 7-8, 2015

Aug 05, 2015: Etubics Platform Shown to Significantly Increase Survival Of End Stage Colorectal Cancer Patients

Jun 22, 2015: Vaxon Biotech granted Japanese patent for new cancer vaccine candidates

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Akshaya Bio Inc, H1 2018
Pipeline by Bavarian Nordic A/S, H1 2018
Pipeline by Etubics Corp, H1 2018
Pipeline by OSE Immunotherapeutics, H1 2018
Pipeline by Vaxon Biotech, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Akshaya Bio Inc

Bavarian Nordic A/S

Etubics Corp

OSE Immunotherapeutics

Vaxon Biotech

I would like to order

Product name: Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/CAC614E3038EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CAC614E3038EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

